News articles about Medpace (NASDAQ:MEDP) have been trending somewhat positive recently, Accern reports. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Medpace earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news stories about the company an impact score of 47.6078735282622 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Several brokerages recently weighed in on MEDP. Jefferies Group increased their price target on shares of Medpace from $34.00 to $38.00 and gave the stock a “hold” rating in a report on Wednesday, November 1st. William Blair downgraded shares of Medpace from an “outperform” rating to a “market perform” rating in a report on Wednesday, November 1st. They noted that the move was a valuation call. BidaskClub upgraded shares of Medpace from a “hold” rating to a “buy” rating in a report on Thursday, December 14th. KeyCorp reiterated a “hold” rating on shares of Medpace in a report on Tuesday, October 17th. Finally, Robert W. Baird increased their price target on shares of Medpace from $32.00 to $35.00 and gave the stock a “neutral” rating in a report on Tuesday, October 31st. Seven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Medpace presently has a consensus rating of “Hold” and a consensus price target of $36.60.

Shares of Medpace (MEDP) traded down $0.67 during midday trading on Friday, hitting $35.13. 49,942 shares of the stock were exchanged, compared to its average volume of 177,927. The firm has a market cap of $1,366.07, a PE ratio of 51.76, a price-to-earnings-growth ratio of 1.55 and a beta of -0.76. Medpace has a twelve month low of $21.76 and a twelve month high of $39.64. The company has a quick ratio of 0.68, a current ratio of 0.68 and a debt-to-equity ratio of 0.36.

In other news, major shareholder Medpace Limited Partnership sold 4,600,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 5th. The shares were sold at an average price of $30.16, for a total transaction of $138,736,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 25.80% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at

Medpace Company Profile

Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.

Insider Buying and Selling by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with's FREE daily email newsletter.